High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer-Reference-Cited by-同舟云学术

High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer

Published:2022-02 Issue:2 Volume:40 Page:63.e9-63.e18
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Sikic Danijel,Eckstein Markus,Weyerer Veronika,Kubon Jennifer,Breyer Johannes,Roghmann Florian,Kunath Frank,Keck Bastian,Erben Philipp,Hartmann Arndt,Wirtz Ralph M.,Wullich Bernd,Taubert Helge,Wach Sven

Funder

Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg

Forschungsstiftung Medizin am Universitätsklinikum Erlangen

Friedrich-Alexander-Universität Erlangen-Nürnberg

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference74 articles.

1. bladder cancer incidence and mortality: a global overview and recent trends;Antoni;Eur Urol,2016

2. EAU guidelines on on-muscle-invasive urothelial carcinoma of the bladder: update 2016;Babjuk;Eur Urol,2017

3. Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG